← Back to patent-cliff list

Apitolisib

Tier C — Watch / trade

Apitolisib

Genentech
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets:mTORC1, mTORC2, Class I PI3K

Indications (approved):Prostate cancer, Breast cancer, Solid tumour, Renal cell carcinoma, Non-Hodgkin lymphoma, Endometrial cancer

Regional status

US
Phase II
2011-10-01
EU
Phase II
2011-10-01
China
-
Japan
-

Synthetic routes & intermediates1 routes

Originator routes × 0Optimised (non-patent) × 0Process routes × 1

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

ProcessRoute 1Steps 10 · Total yield 15.1 kg
APITO-00185006-31-1APITO-00235265-81-7APITO-00335265-83-9APITO-00435265-88-4APITO-005955979-02-9APITO-0061592609-60-3APITO-0071032757-58-6APITO-008936250-22-5APITO-009687-47-8APITO-0101401334-41-5APITO-0117752-82-1APITO-012209959-33-1API · Apitolisib
CodeCAS No.Intermediate
APITO-00185006-31-1Availablemethyl 3-amino-4-methylthiophene-2-carboxylate
APITO-00235265-81-77-methylthieno[3,2-d]pyrimidine-2,4(1H,3H)-dione
APITO-00335265-83-92,4-dichloro-7-methylthieno[3,2-d]pyrimidine
APITO-00435265-88-44-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)morpholine
APITO-005955979-02-92-chloro-7-methyl-4-morpholinothieno[3,2-d]pyrimidine-6-carbaldehyde
APITO-0061592609-60-3(S)-2-hydroxy-1-(piperazin-1-yl)propan-1-one oxalate
APITO-0071032757-58-6(S)-1-(4-((2-chloro-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one
APITO-008936250-22-5(2-aminopyrimidin-5-yl)boronic acid
APITO-009687-47-8ethyl (S)-2-hydroxypropanoate
APITO-0101401334-41-5(S)-2-hydroxy-1-(piperazin-1-yl)propan-1-one
APITO-0117752-82-15-bromopyrimidin-2-amine
APITO-012209959-33-1-

Frequently asked questions

What are the approved indications of Apitolisib?

Approved indications include: Prostate cancer, Breast cancer, Solid tumour, Renal cell carcinoma, Non-Hodgkin lymphoma, Endometrial cancer.

When does the Apitolisib patent expire?

No public expiry year is available for Apitolisib yet; this page updates once verified.

How many synthesis routes are recorded for Apitolisib?

1 synthesis routes are recorded; the shortest is 10 steps with 15.1 kg total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Apitolisib intermediates?

1 intermediate CAS of Apitolisib are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.

How do I get a quote for Apitolisib intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-19